FindTrial
Sign In

Tildrakizumab 100 mg

DRUG4 trials

Sponsors

Sun Pharmaceutical Industries Limited, Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Conditions

Moderate to Severe Genital PsoriasisPlaque Psoriasis

Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
CompletedNCT01722331
Sun Pharmaceutical Industries LimitedPlaque Psoriasis
Start: 2012-12-06End: 2021-11-10Updated: 2022-03-23
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
CompletedNCT01729754
Sun Pharmaceutical Industries LimitedPlaque Psoriasis
Start: 2013-02-05End: 2021-10-26Updated: 2022-03-08
A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
CompletedNCT05108766
Shenzhen Kangzhe Pharmaceutical Co., Ltd.Plaque Psoriasis
Start: 2020-12-17End: 2022-07-08Updated: 2023-04-12
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Active, not recruitingNCT06611163
Sun Pharmaceutical Industries LimitedModerate to Severe Genital Psoriasis
Start: 2025-03-21End: 2027-02-01Updated: 2026-03-25

Related Papers

Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2
Dermatology and Therapy2026-03-16
Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis
British Journal of Dermatology2025-05-133 citations
Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension
Chinese Medical Journal2024-01-099 citations
Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies
Dermatology and Therapy2022-09-1312 citations
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: <i>post hoc</i> analysis of 5‐year data from <scp>reSURFACE</scp> 1 and <scp>reSURFACE</scp> 2
Journal of the European Academy of Dermatology and Venereology2022-04-2320 citations
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
2021-05-0462 citations
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
The Journal of Dermatology2021-02-2511 citations
Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
The Journal of Dermatology2021-02-0114 citations
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
2020-09-1922 citations
Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study
Journal of the European Academy of Dermatology and Venereology2020-05-2011 citations
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
2020-04-3017 citations
Exposure–response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials
British Journal of Clinical Pharmacology2020-03-127 citations
Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis
Journal of the European Academy of Dermatology and Venereology2020-01-1019 citations
Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
2019-08-017 citations
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
2019-07-18109 citations
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
Journal of Dermatological Treatment2019-07-0313 citations
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
2017-06-06400 citations